Background: Acquired von Willebrand factor (VWF) deficiency was described in Philadelphia-
| INTRODUC TI ON
Polycythemia vera (PV) is a BCR/ABL-negative chronic myeloproliferative neoplasm (MPN), characterized by increased erythrocytes production and mass. 1 The genotypic hallmark of PV is the Janus Kinase (JAK) 2-p.V617F mutation, which is a major diagnostic criterion in the 2008 and 2016 World Health Organization (WHO)
classifications, along with increased hemoglobin and hematocrit levels. [2] [3] [4] The JAK2-p.V617F is a gain-of-function mutation resulting in a constitutively activated JAK2 tyrosine kinase, 2 which alters the proliferation of bone marrow cells, gives an advantage to the erythrocytes, and suppresses erythropoietin production.
This mutation occurs in ≥ 95% of patients with PV and in approximately 50% of patients with another MPN that is essential thrombocythemia (ET). 4 The clinical course of PV is characterized by an elevated incidence of venous and arterial thromboses, higher than in the general population. 5, 6 A recent observational study of nearly 10 000 patients with MPN showed that the hazard ratios for arterial thrombosis in patients with PV at 3 months, 1 year, and 5 years from diagnosis were 2.7-fold (95% confidence interval, 2.2-3.3), 1.9-fold (1.6-2.1), and 1.5-fold (1.3-1.7) higher than in the matched general population. Similarly, the hazard ratios for venous thrombosis were 13.1 (8.7-19.6), 5.4 (4.1-7.0), and 3.6 (3.0-4.4) in the same time frame. 7 Due to the increased thrombotic risk associated with PV, antiplatelet prophylaxis with low-dose aspirin is routinely recommended in both primary and secondary cardiovascular prevention, based on the results of the European Collaboration on Low-dose Aspirin in Polycythemia (ECLAP) trial. 6, 8 However, the residual risk of major thrombosis in aspirin-treated patients with PV appears still higher than the risk associated with a non-MPN aspirin-treated matched population, that is, >1%/year, 6,9 also in recent observational studies. 10 Various abnormalities of circulating von Willebrand factor (VWF) have been described in patients with MPNs, usually associated with severe thrombocytosis. [11] [12] [13] The main abnormalities consisted of loss of larger VWF multimers and high proteolysis of VWF, all associated with thrombocytosis, mostly resulting in bleeding. 11, 14, 15 In a previous study on ET, we observed a deficiency of VWF activity and selectively of large VWF multimers over a wide range of platelet counts, rather than in patients with severe thrombocytosis only. 16 This acquired VWF deficiency was likely a continuous phenomenon, driven by high ongoing in vivo platelet activation, which is the hallmark of ET, with consequent platelet-dependent VWF consumption. 17 Defects of VWF multimers have been less frequently reported in PV with thrombocytosis, 18 and considered also responsible for bleeding events. More recently, an acquired but asymptomatic VWF decrease was observed in ≈12% of 142 patients with PV. 19 Interestingly, platelet counts in these patients were still within the normal range and only slightly higher than in patients with normal VWF (390 000 vs 285 000 platelets/µL, respectively). 19 This recent finding appears inconsistent with older studies. 12 We investigated the VWF phenotype and its determinants in a contemporary PV cohort with optimal hematocrit control and ongoing aspirin prophylaxis. Furthermore, we compared the VWF phenotype in 2 matched PV and ET cohorts, to assess whether the VWF pattern is similar or rather disease specific.
| METHODS

| Populations under study
This is an observational, cross-sectional study that included 48 patients with PV diagnosed according to the WHO 2008 criteria for MPNs, 3 and when applicable, criteria were reassessed according to the subsequent WHO 2016 revision. 4 The patients were treated according to current recommendations with phlebotomy ± hydroxyurea to keep the hematocrit ≤ 45%, 20 and all patients were on low-dose aspirin prophylaxis (100 mg once daily). Exclusion criteria were cigarette smoking; clinically significant hepatic, To compare PV and ET, we included data from 41 patients with ET of a previously published cohort by our group, who were selected to match patients with PV based on age, sex, and blood group.
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Essentials
• The von Willebrand factor (VWF) pattern in polycythemia vera (PV) is poorly explored.
• VWF levels in PV were higher than in controls and predicted by JAK2-p.V617 burden and erythrocytes.
• VWF activity in PV was significantly higher than in matched patients with essential thrombocythemia.
• High VWF and factor VIII may favor thrombosis in PV. 16 The deficiency of high-molecular-weight multimers of VWF was defined by the VWF:Act/VWF:Ag ratio < 0.6, that has been shown to reflect a loss of high-molecular-weight multimers, 16 as in the case of type 2A or 2B von Willebrand disease.
| VWF studies
21
FVIII levels were measured by an ELISA method (Diagnostica Stago).
| ADAMTS-13 measurements
The level of ADAMTS-13 antigen was determined using an ELISA kit developed by American Diagnostica Inc (IMUBIND  ® ADAMTS13 ELISA, Sekisui Diagnostics, Lexington, MA, USA). 
| Statistical analysis
Based on our previous study, 7 where VWF:Act levels in patients with ET was reduced by ~ 20% compared to healthy subjects, we assumed a difference of at least 20% between the mean VWF (VWF:Ag and VWF:Act) levels also in patients with PV as compared with healthy subjects. With a standard error < 30% and a power of 0.90, we calculated that 48 PV and 48 control subjects were needed (type I error, 0.05).
The sample size was calculated by using the Power and Sample
Size Program. Bonferroni's correction of data was applied to avoid biases from unequal variance and type I error. Spearman analysis was performed to correlate VWF-related parameters with other hematological parameters. The statistically significant values (P < 0.05) were used as independent variables in multivariable regression analysis (2-sided P < 0.05). 
| RESULTS
| Phenotypic features of VWF in patients with PV as compared to matched healthy subjects
Routine hematological and biochemical characteristics of 48 enrolled patients with PV are listed in Table 1 ; 13 patients had a previous thrombotic event, none had a previous bleeding.
VWF:Ag and VWF:Act levels in patients with PV were significantly higher as compared to VWF:Ag and VWF:Act levels in 48 healthy subjects who were selected to be age, sex, and blood group matched to patients with PV ( Figure 1A ). By contrast, VWF:Act/VWF:Ag ratios were similar in subjects with PV and healthy subjects (0.97 ± 0.1 vs 0.96 ± 0.1, mean ± SD, respectively, P = 0.27). SDS-agarose gel electrophoresis analyses also showed a normal multimeric pattern of VWF in patients with PV, which included the larger multimers ( Figure 2 ). Consistently with increased VWF levels, also FVIII levels were higher in PV than in healthy subjects ( Figure 1B) . Moreover, ADAMTS-13 levels were comparable
TA B L E 1 Characteristics of 48 patients with PV
Parameters Values
Age, y 67. Figure 3A ,B). Moreover, both VWF:Ag and VWF:Act levels were significantly and directly correlated with age, male sex, hydroxyurea treatment and dose, and JAK2-p.V617F allelic burden ( Figure 3C ), while they were inversely correlated with erythrocyte ( Figure 3D ) and platelet counts. The correlation coefficients and level of significance are reported in Table 2 . We did not find any 
| Phenotypic features of VWF in PV compared to matched patients with ET
VWF:Ag and VWF:Act levels in 41 patients with PV were also compared to the levels measured in 41 patients with ET selected from a previously-published cohort to be sex, age, and blood group matched with patients with PV (Table 3) . 16 While VWF:Ag levels were similar in patients with PV and ET ( Figure 4A ), the VWF:Act values were significantly higher in patients with PV as compared to patients with ET ( Figure 4A ), and VWF:Act/VWF:Ag ratios were also higher in patients with PV as compared to patients with ET ( Figure 4B ). The electrophoretic VWF pattern con- 
| DISCUSSION
To our knowledge, this is the first study describing VWF phenotype in a relatively large and contemporary cohort of patients with PV, diagnosed according to revised WHO criteria and treated according 24, 25 Furthermore, previous studies showed that the JAK2-p.
TA B L E 2 Univariate analysis of the main parameters in 48 PV patients
V617F may contribute to a systemic chronic inflammation in
MPNs, mediated by cytokines such as pentraxin-3. 26 Systemic inflammation may also stimulate the release of VWF from ECs. 27 It was also demonstrated that PV erythrocytes with a constitutively activated JAK2 mutant are abnormally adherent to ECs via the erythroid Lutheran/basal cell-adhesion molecule and endothelial laminin. 28, 29 All these findings suggest a prevalent activation and degranulation of ECs in PV that may maintain a high release of VWF into the circulation. 30 High levels of VWF have been shown to be associated with major vascular events in large observational studies of non-MPN patients at high cardiovascular risk, [31] [32] [33] [34] [35] [36] [37] which is consistent with its role as mediator of platelet adhesion to the subendothelial matrix and subsequent platelet activation. 38 Increased levels of VWF may then sustain both macro-and microcirculatory disturbances in PV. In fact, histopathological studies in erythromelalgia show platelet-rich microthrombi, endothelial inflammation, intimal proliferation, and VWF deposition in the microcirculation. 39 As VWF is a physiological chaperone for FVIII, 30 FVIII levels increased in parallel to VWF in PV. High FVIII levels per se are associated with increased venous thromboembolism [40] [41] [42] and may then contribute to venous thromboses in PV. 40 In fact, FVIII accelerates the formation of activated factor X (FXa) and thrombin. 43 Thus, our study suggests that the thrombotic diathesis of PV may be supported by high VWF and FVIII levels in addition to other known pathogenetic factors such as high hematocrit, 44 elevated blood viscosity, 45 platelet activation, 8, 17 and leukocytosis. 46 Notably, patients with previous thrombosis had the highest VWF:Act levels. Therefore, levels of VWF/FVIII should be explored as biomarkers of thrombosis, useful for risk stratification in PV. Further studies are needed to investigate the mechanisms linking JAK2-p.V617F burden, VWF/FVIII, and the thrombotic complications in PV.
Both VWF:Ag and VWF:Act levels in patients with PV were inversely associated with erythrocyte count. A similar association was reported by Mital et al 19 in 142 patients with PV in whom those with VWF:Ag and VWF:Act < 60% and < 50%, respectively, had significantly higher erythrocyte counts. Moreover, PV erythroblasts were found to have increased calreticulin expression on plasma membrane, 47 and calreticulin seems to be involved in the degradation of the circulating VWF/FVIII complex. 48 We also observed a significant association of VWF levels with male sex, not observed in healthy subjects. 49 Interestingly, in a study on over 250 patients with MPN, a significantly higher JAK2-p.V617F allele burden was reported in male versus female patients with PV, even after adjusting for age and disease duration. 50 The direct correlation of JAK2-p.V617F allelic burden with VWF levels ( Figure 3C) may possibly contribute to sex-related difference. Interestingly, PV appears to have a sex-related gene (de)regulation and consequent clinical features. 51 However, the mechanism(s) associating erythrocyte counts and/or sex to VWF phenotype deserve further investigations.
Overall, the VWF phenotype substantially differed between patients with PV and matched patients with ET and appeared rather disease specific. To our knowledge, this is the first study that compared 2 matched PV and ET cohorts, since in other studies PV and ET cohorts were never matched. PV showed no VWF acquired defect with normal VWF:Act/Ag ratio and multimeric pattern.
Differently from patients with PV, patients with ET showed an acquired VWF:Act defect with a clear unbalance between VWF:Ag and VWF:Act and reduced high-molecular-weight VWF multimers.
VWF:Act defect in ET could be inversely predicted only by mature and immature platelet count, 16 while in PV, platelet count was not confirmed in multivariable analysis, where erythrocytes, JAK2 mutation, and male sex were stronger predictors. Therefore, in ET the VWF proteolysis seems prevalent even at relatively lower platelet counts and appears largely driven by the underlying ET-specific abnormal platelet production and activation. 16 Also among JAK2-positive patients with ET a correlation between the mutation burden and VWF levels could not be observed ( Figure 5 ) at variance with previous data. 52 The cause of these differences among ET and PV is unknown, although some hypotheses may be formulated. Recently, the combination of low-dose aspirin and very low-dose rivaroxaban (2.5 mg twice daily) was superior to aspirin alone in reducing major adverse cardiovascular events of patients with stable cardiovascular disorders. 54 Considering that aspirin-treated patients with PV show a residual thrombotic risk comparable to stable cardiovascular patients, in spite of aspirin (up to 4.4%/yr) 6, 55 and that our study suggests a role for FVIII and thrombin generation, the low-dose aspirin and rivaroxaban combination may be beneficial in patients with PV.
Some limitations of our study warrant consideration. Our study is relatively small in size and observational in nature. Another limitation is that mutations other than JAK2-p.V617F 56 were not explored in patients with PV.
In conclusion, VWF and FVIII levels are increased in PV, with no evidence of defects and with a substantially different pattern from ET. VWF and/or FVIII levels may be independent risk factors for thrombosis and may be worth testing as biomarkers of risk stratification of patients with PV. These data provide a rationale for testing combined antithrombotic regimens in PV, which target both platelets and coagulation factor(s).
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